Vanda Pharmaceuticals Inc. Insider Trading for March 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Vanda Pharmaceuticals Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Vanda Pharmaceuticals Inc. for March 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Reverberi Gian Piero | SVP & Chief Commerc ... | Sell | S | 19.92 | 443 | 8,823 | 167,989 | 168.4 K to 168 K (-0.26 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Reverberi Gian Piero | SVP & Chief Commerc ... | Sell | S | 20.17 | 438 | 8,832 | 168,432 | 168.9 K to 168.4 K (-0.26 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Polymeropoulos Mihael Hristos | President and CEO | Sell | S | 19.41 | 38,166 | 740,802 | 1,178,970 | 1.2 M to 1.2 M (-3.14 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Polymeropoulos Mihael Hristos | President and CEO | Sell | S | 20.22 | 6,500 | 131,424 | 1,217,136 | 1.2 M to 1.2 M (-0.53 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Kelly James Patrick | EVP & Chief Financi ... | Sell | S | 19.88 | 8,751 | 173,961 | 209,746 | 218.5 K to 209.7 K (-4.01 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Kelly James Patrick | EVP & Chief Financi ... | Sell | S | 20.15 | 4,976 | 100,271 | 218,497 | 223.5 K to 218.5 K (-2.23 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Birznieks Gunther | SVP, Business Devel ... | Sell | S | 19.89 | 8,788 | 174,767 | 151,251 | 160 K to 151.3 K (-5.49 %) |
| Mar 04 2019 | VNDA | Vanda Pharmaceutic ... | Birznieks Gunther | SVP, Business Devel ... | Sell | S | 20.14 | 3,741 | 75,325 | 160,039 | 163.8 K to 160 K (-2.28 %) |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Reverberi Gian Piero | SVP & Chief Commerc ... | Option Exercise | A | 20.62 | 70,000 | 1,443,400 | 70,000 | |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Reverberi Gian Piero | SVP & Chief Commerc ... | Grant | A | 0.00 | 30,000 | 0 | 168,870 | 138.9 K to 168.9 K (+21.60 %) |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Polymeropoulos Mihael Hristos | President and CEO | Option Exercise | A | 20.62 | 140,000 | 2,886,800 | 140,000 | |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Polymeropoulos Mihael Hristos | President and CEO | Grant | A | 0.00 | 60,000 | 0 | 1,223,636 | 1.2 M to 1.2 M (+5.16 %) |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Kelly James Patrick | EVP & Chief Financi ... | Option Exercise | A | 20.62 | 70,000 | 1,443,400 | 70,000 | |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Kelly James Patrick | EVP & Chief Financi ... | Grant | A | 0.00 | 30,000 | 0 | 223,473 | 193.5 K to 223.5 K (+15.51 %) |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Birznieks Gunther | SVP, Business Devel ... | Option Exercise | A | 20.62 | 70,000 | 1,443,400 | 70,000 | |
| Mar 01 2019 | VNDA | Vanda Pharmaceutic ... | Birznieks Gunther | SVP, Business Devel ... | Grant | A | 0.00 | 30,000 | 0 | 163,780 | 133.8 K to 163.8 K (+22.42 %) |